-+ 0.00%
-+ 0.00%
-+ 0.00%

ARMATA PHARMACEUTICALS RECEIVES $3.7 MILLION IN ADDITIONAL NON-DILUTIVE FUNDING FROM U.S. DEPARTMENT OF WAR TO SUPPORT ADVANCEMENT OF AP-SA02 PHASE 3 DEVELOPMENT

Reuters·09/23/2026 11:00:29

Please log in to view news